Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma.
作者信息
Enssle Julius C, Campe Julia, Büchel Sarah, Moter Alina, See Frederic, Grießbaum Katharina, Rieger Michael A, Wolf Sebastian, Ballo Olivier, Steffen Björn, Serve Hubert, Rabenau Holger F, Widera Marek, Bremm Melanie, Huenecke Sabine, Ciesek Sandra, von Metzler Ivana, Ullrich Evelyn
机构信息
Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany; Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Frankfurt partner site, Germany.
Experimental Immunology, Department for Children and Adolescents Medicine, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany; Division of Pediatric Stem Cell Transplantation and Immunology, Department for Children and Adolescents Medicine, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany; Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany.
出版信息
Cancer Cell. 2022 Jun 13;40(6):587-589. doi: 10.1016/j.ccell.2022.05.003. Epub 2022 May 8.
Abstract
摘要
相似文献
1
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma.多发性骨髓瘤患者对第三剂BNT162b2疫苗接种的血清学和细胞免疫反应增强但因变体而异。
Cancer Cell. 2022 Jun 13;40(6):587-589. doi: 10.1016/j.ccell.2022.05.003. Epub 2022 May 8.
2
Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals.接种 BNT162b2 疫苗加强针 5 个月后老年人对 Delta 和奥密克戎变异株特异性抗体滴度的下降
Front Immunol. 2022 Nov 14;13:1031852. doi: 10.3389/fimmu.2022.1031852. eCollection 2022.
3
Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.COVID-19 加强针接种后免疫反应的持久性及其与 COVID-19 奥密克戎感染的关联。
JAMA Netw Open. 2022 Sep 1;5(9):e2231778. doi: 10.1001/jamanetworkopen.2022.31778.
4
BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages.BNT162b2 加强针接种在各年龄段康复者中引发针对 SARS-CoV-2 变体 B.1.1.529 和 B.1.617.2 的交叉反应性免疫。
Front Immunol. 2022 Jun 20;13:920210. doi: 10.3389/fimmu.2022.920210. eCollection 2022.
5
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.6 个月时对接受第三剂 BNT162b2 抗 SARS-CoV-2 疫苗的实体瘤患者的体液和细胞免疫反应：一项关注关注重点变体的纵向队列研究。
ESMO Open. 2022 Oct;7(5):100574. doi: 10.1016/j.esmoop.2022.100574. Epub 2022 Aug 5.
6
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.SARS-CoV-2-mRNA 加强疫苗接种逆转免疫功能低下患者的无反应性和早期抗体衰减 - 一项比较实体瘤、多发性骨髓瘤和炎症性肠病患者免疫反应的四期研究。
Front Immunol. 2022 May 12;13:889138. doi: 10.3389/fimmu.2022.889138. eCollection 2022.
7
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response.免疫应答：SARS-CoV-2 mRNA 疫苗接种和加强剂在多发性骨髓瘤和单克隆丙种球蛋白病患者中的作用：Omicron 变异对体液免疫应答的影响。
Oncoimmunology. 2022 Sep 6;11(1):2120275. doi: 10.1080/2162402X.2022.2120275. eCollection 2022.
8
Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.同源和异源 BNT162b2、CoronaVac 和 AZD1222 加强疫苗对 Delta 和奥密克戎 SARS-CoV-2 感染的真实世界有效性。
Emerg Microbes Infect. 2022 Dec;11(1):1343-1345. doi: 10.1080/22221751.2022.2072773.
9
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
10
Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.mRNA 疫苗加强针在西班牙针对 SARS-CoV-2 奥密克戎（B.1.1.529）变异株感染的有效性：一项全国性队列研究。
Lancet Infect Dis. 2022 Sep;22(9):1313-1320. doi: 10.1016/S1473-3099(22)00292-4. Epub 2022 Jun 2.
引用本文的文献
1
Immune responses after one versus two Influenza A/B vaccinations in patients with multiple myeloma.多发性骨髓瘤患者接种一剂与两剂甲型/乙型流感疫苗后的免疫反应。
Ann Hematol. 2025 May;104(5):2813-2821. doi: 10.1007/s00277-025-06367-1. Epub 2025 May 15.
2
Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment.甘露糖修饰的脂质磷酸钙纳米颗粒疫苗通过调节肿瘤微环境增强抗肿瘤免疫反应。
J Funct Biomater. 2024 Aug 16;15(8):229. doi: 10.3390/jfb15080229.
3
Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants.接种SARS-CoV-2疫苗的多发性骨髓瘤患者中的突破性感染改善了对奥密克戎变种的交叉保护。
Vaccines (Basel). 2024 May 9;12(5):518. doi: 10.3390/vaccines12050518.
4
Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis.系统评价和荟萃分析：多发性骨髓瘤患者对 COVID-19 疫苗接种的免疫反应。
BMC Geriatr. 2024 May 8;24(1):411. doi: 10.1186/s12877-024-05006-0.
5
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.血液系统恶性肿瘤患者和老年人群对三剂抗 SARS-CoV-2 BNT162b2 疫苗的体液和细胞反应动力学。
Front Immunol. 2024 Jan 26;14:1221587. doi: 10.3389/fimmu.2023.1221587. eCollection 2023.
6
COVID-19 vaccine immune response in patients with plasma cell dyscrasia: a systematic review.浆细胞发育异常患者的COVID-19疫苗免疫反应：一项系统综述
Ther Adv Vaccines Immunother. 2023 Aug 27;11:25151355231190497. doi: 10.1177/25151355231190497. eCollection 2023.
7
Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination.B 细胞血液恶性肿瘤患者对 SARS-CoV-2 的体液和细胞反应随着连续接种疫苗而改善。
Br J Haematol. 2023 Sep;202(6):1091-1103. doi: 10.1111/bjh.18962. Epub 2023 Jul 4.
8
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma.活动性多发性骨髓瘤患者对SARS-CoV-2 mRNA疫苗的体液和细胞反应的长期随访
Front Oncol. 2023 May 25;13:1208741. doi: 10.3389/fonc.2023.1208741. eCollection 2023.
9
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.成年癌症患者对新冠病毒疫苗全程接种和加强针的体液免疫反应受损，尤其是正在接受积极治疗的血液系统癌症患者：一项系统评价和荟萃分析。
Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.
10
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).《后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理：来自欧洲骨髓瘤网络（EMN）的共识文件》。
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
本文引用的文献
1
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients.骨髓瘤患者第三次接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后的体液免疫和细胞免疫反应增强及病毒中和作用
Cancer Cell. 2022 May 9;40(5):441-443. doi: 10.1016/j.ccell.2022.03.013. Epub 2022 Apr 6.
2
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement.SARS-CoV-2 奥密克戎免疫逃逸和受体结合的结构基础。
Science. 2022 Feb 25;375(6583):864-868. doi: 10.1126/science.abn8652. Epub 2022 Jan 25.
3
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network.COVID-19 疫苗接种在多发性骨髓瘤患者中的应用：欧洲骨髓瘤网络共识。
Lancet Haematol. 2021 Dec;8(12):e934-e946. doi: 10.1016/S2352-3026(21)00278-7. Epub 2021 Oct 28.
4
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.多发性骨髓瘤完全接种疫苗患者对SARS-CoV-2的细胞反应各异。
Cancer Cell. 2021 Nov 8;39(11):1442-1444. doi: 10.1016/j.ccell.2021.09.015. Epub 2021 Oct 19.
5
COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view.COVID-19 与多发性骨髓瘤：从短期和长期来看多发性骨髓瘤患者对 SARS-CoV-2 的细胞和体液免疫。
J Mol Med (Berl). 2022 Mar;100(3):463-470. doi: 10.1007/s00109-021-02114-x. Epub 2021 Oct 18.
6
Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.多发性骨髓瘤患者对BNT162b2免疫接种的T细胞反应严重受损。
Blood. 2022 Jan 6;139(1):137-142. doi: 10.1182/blood.2021013429.
7
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.癌症患者接种新冠病毒mRNA疫苗后的抗体和T细胞免疫反应。
Cancer Cell. 2021 Aug 9;39(8):1034-1036. doi: 10.1016/j.ccell.2021.07.016. Epub 2021 Jul 27.
8
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.多发性骨髓瘤患者对两剂新冠病毒RNA疫苗的严重急性呼吸综合征冠状病毒2刺突抗体反应高度可变。
Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29.
9
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.中和抗体水平高度预测对有症状的 SARS-CoV-2 感染的免疫保护作用。
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
10
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.与 COVID-19 多发性骨髓瘤患者结局相关的临床特征：国际骨髓瘤学会数据集的初步结果。
Blood. 2020 Dec 24;136(26):3033-3040. doi: 10.1182/blood.2020008150.
Zotero 插件